The BULLSEYE trial and PSMA radioligands

Dr. Barbara Melão (Brazil) and Dr. Danny Mena (Mexico) open Season 2 with GU oncology and the latest advances in prostate cancer care.

Key insights

  • The rationale behind the BULLSEYE trial
  • Key differences between lutetium and terbium
  • Understanding affinity versus toxicity
  • Follow-up strategies for patients with PSMA PET

More episodes